GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » 3-Year EPS without NRI Growth Rate

Caplin Point Laboratories (BOM:524742) 3-Year EPS without NRI Growth Rate : 23.80% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories 3-Year EPS without NRI Growth Rate?

Caplin Point Laboratories's EPS without NRI for the three months ended in Mar. 2024 was ₹16.01.

During the past 12 months, Caplin Point Laboratories's average EPS without NRI Growth Rate was 21.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 23.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Caplin Point Laboratories was 82.00% per year. The lowest was 18.80% per year. And the median was 52.30% per year.


Competitive Comparison of Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate falls into.



Caplin Point Laboratories 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Caplin Point Laboratories  (BOM:524742) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Caplin Point Laboratories 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Caplin Point Laboratories (BOM:524742) Business Description

Traded in Other Exchanges
Address
Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines